Effect of vascular endothelial growth factor and epidermal growth factor on iatrogenic apoptosis in human endothelial cells

被引:29
|
作者
Vinci, MC
Visentin, B
Cusinato, F
Nardelli, GB
Trevisi, L
Luciani, S [1 ]
机构
[1] Univ Padua, Dept Pharmacol & Anaesthesiol, Padua, Italy
[2] Univ Padua, Dept Gynaecol Sci & Human Reprod, Padua, Italy
关键词
apoptosis; staurosporine; VEGF; EGF; PI-3; kinase; ERKs;
D O I
10.1016/j.bcp.2003.09.007
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
To study the effect of growth factors on iatrogenic apoptosis, we examined the influence of vascular endothelial growth factor (VEGF) and epidermal growth factor (EGF) on staurosporine-induced apoptosis in primary cultures of human umbilical vein endothelial cells (HUVEC). Apoptosis was evaluated by a cell viability test, the TUNEL-POD assay and the activation of the pro-apoptotic caspase-3. Staurosporine (10-100 nM) caused the activation of caspase-3. This effect was manifest after 2 hr of incubation and reached its maximum after 5 hr. Severe loss of viability followed within 18 hr. VEGF or EGF (10-100 ng/mL) added together with staurosporine decreased the activation of caspase-3. The loss of viability was 24 hr delayed. The action of growth factors was observed at 1% serum concentration but also at concentration optimal for HUVEC survival (10%, v/v). Furthermore, the inhibition of PI-3 kinase (PI-3K) by wortmannin or LY294002 as well as the inhibition of MEK by PD098059 or U0126 prevented the protective effect of VEGF and EGF. Western blotting analysis showed that after 3 hr of incubation with staurosporine the level of the anti-apoptotic protein Mcl-1 decreased and this effect was reverted by VEGF. It is concluded that VEGF and EGF antagonize the pro-apoptotic action of staurosporine by the combined signalling of PI-3K and ERKs pathways. (C) 2003 Elsevier Inc. All rights reserved.
引用
收藏
页码:277 / 284
页数:8
相关论文
共 50 条
  • [41] The Vascular endothelial growth factor
    Zouggari, Yasmine
    [J]. SANG THROMBOSE VAISSEAUX, 2009, 21 (9-10): : 494 - 496
  • [42] Vascular endothelial growth factor
    Plate, KH
    Warnke, PC
    [J]. JOURNAL OF NEURO-ONCOLOGY, 1997, 35 (03) : 365 - 372
  • [43] Vascular endothelial growth factor
    Ferrara, N
    [J]. EUROPEAN JOURNAL OF CANCER, 1996, 32A (14) : 2413 - 2422
  • [44] Vascular endothelial growth factor
    Karl H. Plate
    Peter C. Warnke
    [J]. Journal of Neuro-Oncology, 1997, 35 (3) : 363 - 370
  • [45] Vascular Endothelial Growth Factor
    Ferrara, Napoleone
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2009, 29 (06) : 789 - 791
  • [46] Lipopolysaccharide-induced apoptosis of endothelial cells and its inhibition by vascular endothelial growth factor
    Munshi, N
    Fernandis, AZ
    Cherla, RP
    Park, IW
    Ganju, RK
    [J]. JOURNAL OF IMMUNOLOGY, 2002, 168 (11): : 5860 - 5866
  • [47] Vascular endothelial growth factor
    Marti, HH
    [J]. MOLECULAR AND CELLULAR BIOLOGY OF NEUROPROTECTION IN THE CNS, 2002, 513 : 375 - 394
  • [48] Vascular endothelial growth factor inhibits lipopolysaccharide-induced apoptosis of endothelial cells.
    Munshi, N
    Ganju, RK
    Park, IW
    Groopman, JE
    [J]. BLOOD, 2000, 96 (11) : 41A - 41A
  • [49] Vascular endothelial growth factor induces heparin-binding epidermal growth factor-like growth factor in vascular endothelial cells. (vol 273, pg 4400, 1998)
    Arkonac, BM
    Foster, LC
    Sibinga, NES
    Paterson, C
    Lai, KH
    Tsai, JC
    Lee, ME
    Perrella, MA
    Haber, E
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (15) : 9352 - 9352
  • [50] The vascular endothelial growth factor (VEGF) as an autocrine and resistance factor to apoptosis in human prostate cancer cells(LNCaP)
    Colon, NM
    Buttyan, R
    [J]. MOLECULAR BIOLOGY OF THE CELL, 1999, 10 : 40A - 40A